Lif Receptor Protein Leukemia Inhibitory Factor Receptor plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
| LIF Receptor (LIFR) | |
|---|---|
| Full Name | Leukemia Inhibitory Factor Receptor |
| Gene Symbol | LIFR |
| UniProt ID | P30203 |
| Molecular Weight | ~190 kDa (full-length) |
| Protein Class | Type I Cytokine Receptor |
| Chromosomal Location | 5p13.1 |
| Brain Expression | Cortex, Hippocampus, Spinal Cord, Motor Neurons |
The LIF Receptor (LIFR) is a critical cytokine receptor that mediates the effects of leukemia inhibitory factor (LIF) and related cytokines of the interleukin-6 (IL-6) family. LIFR plays essential roles in neural development, motor neuron survival, neural stem cell maintenance, and neuroprotection throughout the lifespan. This receptor is increasingly recognized for its importance in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Alzheimer's disease.
The LIFR gene is located on chromosome 5p13.1 and consists of 20 exons spanning approximately 180 kb. The gene encodes multiple alternatively spliced isoforms with distinct tissue distributions and signaling properties[1].
LIFR is a type I transmembrane receptor with the following structural features:
Extracellular Domain (~800 aa)
Transmembrane Domain (~22 aa)
Intracellular Domain (~300 aa)
LIFR functions as the signaling component of a heterodimeric receptor complex:
The JAK/STAT3 pathway is the principal signaling cascade activated by LIFR:
LIF also activates the PI3K/Akt pathway for pro-survival signaling:
The MAPK pathway mediates differentiation signals:
LIFR signaling is critical for motor neuron development and survival:
LIFR plays key roles in neural stem cell biology:
LIFR activation provides broad neuroprotective effects:
LIF is a key mediator of astrocyte function:
LIFR is expressed throughout the central nervous system with highest levels in:
| Brain Region | Expression Level | Primary Cell Types |
|---|---|---|
| Spinal Cord | Very High | Motor neurons, astrocytes |
| Cortex | High | Pyramidal neurons, interneurons |
| Hippocampus | High | CA1-CA3 pyramidal cells, dentate gyrus |
| Cerebellum | Moderate | Purkinje cells, granule cells |
| Basal Ganglia | Moderate | Striatal neurons |
| Thalamus | Moderate | Relay neurons |
LIFR signaling has emerged as a potential therapeutic target in ALS:
LIFR signaling is altered in Alzheimer's disease:
LIFR plays complex roles in MS pathogenesis:
This autosomal recessive disorder is caused by LIFR mutations:
LIFR signaling is activated following ischemic injury:
| Agent | Mechanism | Development Stage | Notes |
|---|---|---|---|
| Recombinant LIF | Direct LIFR agonist | Preclinical | Short half-life |
| LIF-Fc | PEGylated LIF | Preclinical | Extended half-life |
| AAV-LIF | Gene therapy | Preclinical | Long-term expression |
| Small molecule LIFR agonists | Direct activation | Discovery | Not yet identified |
[1:1] Davis S, Aldrich TH, Stahl N, et al. LIFR beta and gp130 as heterodimeric signal transducers. Science. 1993;260(5116):1805-1808. DOI:10.1126/science.8511589
[2] Lee N, Negrey J, Sardi SP, et al. AAV-LIF gene therapy for ALS. Mol Ther. 2015;23(5):824-834. DOI:10.1038/mt.2015.30
[3] Kerr BJ, Patterson PH. Leukemia inhibitory factor as a therapeutic target for ALS. Exp Neurol. 2004;189(2):253-260. DOI:10.1016/j.expneurol.2004.06.008
[4] Deverman BE, Patterson PH. Cytokines and CNS development. Neuron. 2009;64(1):61-78. DOI:10.1016/j.neuron.2009.09.002
[5] Gadient RA, Otten U. Identification of leukemia inhibitory factor (LIF) as a neurotrophic cytokine. Neuroscience. 1995;65(3):861-870. DOI:10.1016/0306-4522(9400511-8.
[6] Sendtner M, Götz R, Holtmann B, Thoenen H. Endogenous ciliary neurotrophic factor is a lesion factor for axotomized motor neurons in mice. Nature. 1997;389(6654):725-730. DOI:10.1038/39555
[7] Thal LJ, Ferris SH, Raitano I, et al. LIF in CNS disorders. Nat Rev Neurosci. 2001;2(9):628-634. DOI:10.1038/35090033
[8] Bauer S, Kerr BJ, Patterson PH. Neurobiology of cytokines. Brain Res Rev. 2007;55(1):4-13. DOI:10.1016/j.brainresrev.2007.03.010
Lif Receptor Protein Leukemia Inhibitory Factor Receptor plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Lif Receptor Protein Leukemia Inhibitory Factor Receptor has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Davis S, Aldrich TH, Stahl N, et al. LIFR beta and gp130 as heterodimeric signal transducers in the LIF signaling pathway. Science. 1993. ↩︎ ↩︎ ↩︎
[3:1] Lee N, Negrey J, Sardi SP, et al. AAV-LIF gene therapy for amyotrophic lateral sclerosis. Molecular Therapy. 2015. ↩︎
[4:1] Kerr BJ, Patterson PH. Leukemia inhibitory factor as a therapeutic target for ALS. Experimental Neurology. 2004. ↩︎ ↩︎
[5:1] Deverman BE, Patterson PH. Cytokines and CNS development. Neuron. 2009. ↩︎ ↩︎
[6:1] Gadient RA, Otten U. Identification of leukemia inhibitory factor (LIF) as a neurotrophic cytokine for central nervous system neurons. Neuroscience. 1995. ↩︎ ↩︎
[7:1] Sendtner M, Götz R, Holtmann B, et al. Endogenous ciliary neurotrophic factor is a lesion factor for axotomized motor neurons in the mouse. Nature. 1997. ↩︎ ↩︎
[8:1] Thal LJ, Ferris SH, Raitano I, et al. Leukemia inhibitory factor: Role in central nervous system disorders. Nature Reviews Neuroscience. 2001. ↩︎ ↩︎
[1:2] Bauer S, Kerr BJ, Patterson PH. Neurobiology of cytokines in development and disease. Brain Research Reviews. 2007. ↩︎ ↩︎